Trial results for a study investigating pharmacy-based pre-exposure prophylaxis (PrEP) for HIV were posted on ClinicalTrials.gov on 2025-05-28, reporting that 2 participants continued PrEP in the intervention group.
Background
Human Immunodeficiency Virus (HIV) remains a significant global health challenge, with prevention strategies like pre-exposure prophylaxis (PrEP) playing a crucial role in reducing new infections. PrEP involves taking medication to prevent HIV acquisition. Despite its effectiveness, disparities in PrEP uptake and adherence persist, particularly among certain populations such as Black men who have sex with men (BMSM) living in high-poverty, racial minority neighborhoods. Innovative delivery models, such as pharmacy-based PrEP, are being explored to improve access and increase uptake in these communities, aiming to reduce HIV incidence and address racial inequities in HIV prevention.
Trial design
This completed study, designated as Phase NA, enrolled 49 participants to investigate conditions including Human Immunodeficiency Virus. The trial focused on developing a culturally appropriate pharmacy PrEP delivery model specifically for Black men who have sex with men (BMSM) residing in high-poverty, racial minority neighborhoods. The primary goal was to explore the potential of increasing PrEP access through pharmacies to enhance uptake among BMSM.
Key results
The trial reported on the number of participants continuing PrEP within the intervention group:
- For the "Pharmacy Delivered PrEP Intervention" group, the Number of Participants Continuing PrEP was 2 Participants.
What this means
The reported outcome of 2 participants continuing PrEP in the pharmacy-delivered intervention group provides initial data on the feasibility and immediate continuation rates of this specific model. While the study aimed to increase PrEP access and uptake among Black men who have sex with men (BMSM) in high-poverty areas, this specific measurement highlights the number of participants who maintained PrEP within the study's timeframe. This information contributes to understanding the initial engagement and continuation challenges or successes of pharmacy-based PrEP delivery models in vulnerable populations.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04393935, titled "Pharmacy-based Pre-exposure Prophylaxis", were posted on 2025-05-28 on clinicaltrials.gov.